This guideline covers diagnosing and managing prostate cancer in secondary care. It offers information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It includes recommendations on follow-up in primary care for men with diagnosed prostate cancer.
This guideline includes recommendations on:
- information and support
- localised and locally advanced prostate cancer
- hormone therapy
- metastatic prostate cancer
Who is it for?
- Health professionals
- Men diagnosed with prostate cancer, their families and carers.
Is this guideline up to date?
We reviewed the evidence in October 2016, through an exceptional review, and we are updating the recommendations in 3 areas of the guideline.
Guideline development process
This guideline updates and replaces prostate cancer: diagnosis and treatment (CG58) and denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (TA194).
This guideline was previously called prostate cancer: diagnosis and treatment.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.